Anthem Biosciences IPO Date, Price, Details
Anthem Biosciences IPO is expected to open in 2025 and will close the same year. The offer is structured as a Book Built Issue, with a total fundraising target of approximately ₹3,395 crores. This includes both a fresh issue and an offer for sale of equity shares with a face value of ₹2 each. Exact details regarding the size of each component are yet to be disclosed.
The price band is currently unspecified. The share allocation is divided as follows: 50% for QIBs, 35% for retail investors, and 15% for HNIs. The IPO will be listed on the BSE and NSE, and the basis of allotment is scheduled for 2025.
In terms of financial performance, the company posted a revenue of ₹1,483.07 crores in FY 2024, up from ₹1,133.99 crores in FY 2023. Net profit, however, declined slightly to ₹367.31 crores in FY 2024 from ₹385.19 crores the year before.
Anthem Biosciences IPO Market Lot Size
The Anthem Biosciences IPO minimum market lot is [.] shares with ₹[.] application amount. The retail investors can apply up-to 13 lots with [.] shares of ₹[.] amount.
Application | Lot Size | Shares | Amount |
Retail Minimum | 1 | – | ₹- |
Retail Maximum | 13 | – | ₹- |
S-HNI Minimum | 14 | – | ₹- |
B-HNI Minimum | 68 | – | ₹- |
Anthem Biosciences IPO Details
IPO Open Date: | 2025 |
IPO Close Date: | 2025 |
Face Value: | ₹2 Per Equity Share |
IPO Price Band: | ₹[.] to ₹[.] Per Share |
Issue Size: | Approx ₹3,395 Crores |
Fresh Issue: | Approx ₹3,395 Crores |
Offer for Sale: | Approx [.] Equity Shares |
Issue Type: | Book Build Issue |
IPO Listing: | BSE & NSE |
Retail Quota: | Not more than 35% |
QIB Quota: | Not more than 50% |
NII Quota: | Not more than 15% |
Anthem Biosciences IPO Valuation – FY2024 (KPI)
Check Anthem Biosciences IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
KPI | Values |
ROE: | 20.04% |
ROCE: | 25.22% |
EBITDA Margin: | 36.25% |
PAT Margin: | 24.77% |
Debt to equity ratio: | 0.12 |
Earning Per Share (EPS): | ₹6.48 (Basic) |
Price/Earning P/E Ratio: | N/A |
Return on Net Worth (RoNW): | 20.03% |
Net Asset Value (NAV): | ₹34.43 |
Anthem Biosciences IPO Company Financial Report
In FY 2024, the company generated revenue of ₹1,483.07 crores, marking an increase from ₹1,133.99 crores in FY 2023. However, net profit declined slightly to ₹367.31 crores in 2024, compared to ₹385.19 crores in the previous year.
(All amounts are in ₹ crores.)
Period Ended | Revenue | Expense | Profit After Tax | Assets |
2022 | ₹1,280.24 | ₹734.10 | ₹405.54 | ₹1,618.87 |
2023 | ₹1,133.99 | ₹698.50 | ₹385.19 | ₹2,014.46 |
2024 | ₹1,483.07 | ₹1,005.75 | ₹367.31 | ₹2,398.11 |
September 2024 | ₹910.85 | ₹593.34 | ₹244.31 | ₹2,692.51 |
Anthem Biosciences IPO Dates
The Anthem Biosciences IPO date is 2025 and the close date is 2025. The Anthem Biosciences IPO allotment will be finalized on 2025 and the IPO listing on 2025.
| IPO Open Date: | July 14, 2025 |
| IPO Close Date: | July 16, 2025 |
| Basis of Allotment: | July 17, 2025 |
| Refunds: | July 18, 2025 |
| Credit to Demat Account: | July 18, 2025 |
| IPO Listing Date: | July 21, 2025 |
Promoters of Anthem Biosciences IPO
The promoters of the company are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj.
About Anthem Biosciences IPO
Anthem Biosciences Limited, established in 2006, is a rapidly expanding, innovation-led Contract Research, Development, and Manufacturing Organization (CRDMO). The company offers comprehensive, end-to-end solutions spanning the entire pharmaceutical lifecycle—from drug discovery and early-stage development to commercial manufacturing.
What sets Anthem apart is its integrated expertise in both New Chemical Entities (NCEs) and New Biological Entities (NBEs), making it one of the few Indian players with capabilities that extend across the full drug development value chain.
As a full-service partner, Anthem Biosciences supports a diverse global clientele that ranges from emerging biotech firms to some of the world’s leading pharmaceutical companies. Its core manufacturing focus includes fermentation-derived active pharmaceutical ingredients (APIs) such as probiotics, enzymes, peptides, biosimilars, nutritional actives, and vitamin derivatives.
As of March 31, 2024, the company has served over 150 clients worldwide and operates with a skilled team of approximately 600 professionals, including medicinal chemists, molecular biologists, microbiologists, chemical engineers, and biochemists, all working together to support global healthcare innovation.
Peer Group Comparison
Company | EPS | PE Ratio | RoNW % | NAV | Income |
Syngene International Limited | 12.71 | 67.23 | 12.95% | 105.91 | 3,579.20 Cr. |
Sai Life Sciences Limited | 4.57 | 168.94 | 8.89% | 53.83 | 1,494.27 Cr. |
Suven Life Sciences Limited | 11.80 | 105.67 | 15.86% | 80.56 | 1,113.26 Cr. |
Divi’s Laboratories Limited | 60.27 | 97.03 | 12.15% | 511.21 | 8,184.00 Cr. |
Objects of the IPO
Merchant Bankers
- Jm Financial Limited
- Citigroup Global Markets India Private Limited
- J.P. Morgan India Private Limited
- Nomura Financial Advisory And Securities (India) Pvt Ltd
Company Address
Anthem Biosciences Limited
No. 49, F1 & F2, Canara Bank Road
Bommasandra Industrial Area, Phase 1,
Bommasandra,
Bengaluru, Karnataka, 560099
Phone: +91 080 6672 400
Email: [email protected]
Website: https://www.anthembio.com/
Anthem Biosciences IPO Registrar
KFin Technologies Limited
Phone: 04067162222, 04079611000
Email: [email protected]
Website: https://kosmic.kfintech.com/ipostatus/
Check Grey market premium at below
(GMP)